Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200007/S002

HeartSync Multifunction Disposable Single-Use Defibrillator Pads

Graphic Controls D.B.A. Vermed · Decision date Dec 19, 2025

FDA DECISIONP200007/S002

What did the FDA decide?

FDA records P200007/S002 as a supplement to PMA P200007, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 19, 2025.

FDA approval order statement

a modification of the primary packaging pouch for the HeartSync Multifunction Disposable Single-Use AED defibrillator pad, T100AC-Zoll-10, and T100-CS
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Dec 19, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P200007/S002
Regulatory pathway
PMA supplement
Product code
MKJ
Decision code
OK30
Decision date
Dec 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Automated external defibrillators (non-wearable).

Product code
MKJ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P200007/S001 · Related supplement

    HeartSync Multifunction Disposable Single-Use AED Defibrillator Pads

  2. P200007/S002 received

    Application receipt date recorded by FDA.

  3. P200007/S002 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P200007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200007

Product / regulatory recordCompanyPathwayDecision dateSource
Graphic Controls D.B.A. VermedPMA supplementNov 12, 2025FDA

Explore the linked device profile

Other records with product code MKJ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Graphic Controls D.B.A. Vermed

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
400 Exchange St., Buffalo, NY, 14204

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records